Company
Egle Therapeutics
Pioneering precision medicines that modulate regulatory T cells to rebalance immune function in patients with autoimmune diseases and cancer.
- Status
- Operatingas of 2026-09-18Source (opens in a new tab)
- Business model
- B2B
- Headquarters
- Paris, France
Claim, correct or request removal
Record updated 28 September 2026
About
Egle Therapeutics is a clinical-stage biotechnology company pioneering precision medicines that modulate regulatory T cells (Tregs) to rebalance immune function in patients with autoimmune diseases and cancer.
Funding snapshot
- Latest round
- Grant2026-03-02
Funding rounds
- Grant
- 2026-03-02
Products
- Other
- EGL-001
- Other
- EGL-002
- Other
- EGL-003
Loading relationship preview